In contrast, fear, being seen related to or independent of anxiety, may be defined as the reaction to a potentially dangerous situation, which is already real and well-defined. While responsive to variable external demands, anxiety as used in this article refers to the basal (i.e. not stressbased), inborn trait. However, to make anxietyrelated behavior including its neuroendocrine correlates measurable, the animals have to be exposed to more or less stressful situations. In this context, I would like not to distinguish between anxiety and (unconditioned) fear. Emotionality, often used as a synonym for anxiety as well as fearfulness, may be seen in a broader sense, comprising both inborn anxiety and stimulus-related fear. Of course, all these constructs are closely related to stress and adaptive capabilities. Importantly, being in interaction with stress phenomena, emotionality can simultaneously affect and be affected by all the behavioral, neuroendocrine etc. changes occurring during stress. Due to this complexity, it is by far not trivial to unambiguously relate certain alterations to anxiety rather than to more unspecific stress mechanisms that often contaminate anxiety.
As mentioned above, anxiety may be interpreted as an emotional anticipation of an aversive situation, difficult to predict and control, which is likely to occur. Fear is not seen as a basal state (as is anxiety), but a complex response (e.g. freezing, startle, increased vigilance) elicited during danger to facilitate appropriate defensive behaviors that can reduce danger or injury (e.g. escape, avoidance). In both animals and humans, anxiety and fear are characterized not only by harm-avoidance behavior but also by a bias favoring negative associations in assessing the emotional quality of a situation. This includes a bias for interpreting ambiguous scenarios as potentially threatening, an attentional bias favoring the selective processing of threat cues and a bias of explicit memory for threat. Despite fear being seen by some authors as independent of anxiety, the distinction between these two constructs is often difficult. Even in the clinic, different types of fear-related phobias are subclasses of the so-called anxiety disorders. In contrast to anxiety and unconditioned fear, conditioning models almost invariably require extensive training and essential controls for non-specific treatment effects on learning and memory. While learned fear, typically produced by Pavlovian conditioning, has a lower degree of ecological validity and is more susceptible to influences arising from interference with motivational and cognitive processes, it is less prone to variable behavioral baselines. Research on learned fear has been instrumental in advancing our understanding of the neurobiology of fear. In contrast, anxiety and unconditioned fear have not been studied in as much depth. Furthermore, we are just beginning to understand the physiological involvement of neuropeptides in mechanisms underlying both anxiety/unconditioned fear and conditioned fear.
Importantly, if one focuses on neuroendocrine correlates of anxiety-and fear-related behavior, anxiogenic stimuli like electric foot shocks per se are likely to elicit stress responses which are not distinguishable from emotionality-related responses. At best, stress-based models might prove to be valid as models of a state of anxiety or a state of depression. Because anxiety, rather than stimulus-specific fear, is a major problem in many types of psychiatric disorders inclusive of panic disorders and endogenous depression, identifying neuroendocrine correlates of inborn anxiety in proper animal models could ultimately lead to more effective and causal treatment strategies. Can anxiety-related behavior in rodents really reflect anxiety disorders and depression in patients? Most importantly, there are the same pathways underlying both physiological and pathological anxiety; in other words, pathological anxiety evolves directly from normal anxiety and fear [1] . Furthermore, there are neuroanatomical parallels with human anxiety. A variety of brain areas is involved in the evaluation and assessment of the anxiety-inducing nature of internal and external stimuli [2, 3] . Briefly, these stimuli are first processed in the sensory cortex prior to the transfer to subcortical structures which are involved in affective, somatic and neuroendocrine responses. Many of these circuits contain neuropeptides acting as neurotransmitters/neuromodulators.
In particular the amygdala receives highly processed sensory information from all modalities through its lateral and basolateral nuclei. In turn, these nuclei project to the central nucleus of the amygdala, which then projects to a variety of brain areas that mediate specific signs of anxiety and fear, thus orchestrating emotional reactivity. Simultaneously, the stimulus-related sensory inputs are projected to other cortical areas capable of incorporating an individual's prior experience (i. e. memory) into the cognitive and emotional appraisal of a given situation. Cognitive and emotional aspects then provide a framework for initiation of coping strategies based upon the quality of the stimulus, prior experience, and the inborn emotionality of the individual. Therefore, fear, anxiety and the susceptibility to anxiety, respectively, comprise a variety of neuronal circuits including those in the cortex, hypothalamus and amygdala including the bed nucleus of the stria terminalis (which is considered to be part of the so-called extended amygdala). Interestingly, the bed nucleus of the stria terminalis may respond to signals more akin to anxiety than fear, whereas the central nucleus of the amygdala is clearly involved in fear and perhaps less in anxiety [4] .
Animal models provide the advantage that the substrate that generates emotions, namely the brain, is accessible. Proper psychopathological animal models have to fulfill the requirement of face validity (phenomenological similarities between the model and the condition being modeled), predictive validity (success of predictions made from the model), and construct validity (theoretical rationale). Social defeat, for example, an often used emotional and naturally occurring stressor, has construct validity in adverse, real life events; defeat and chronic stress have been recognized as predisposing factors in the etiology of anxiety disorders and depression. They appear to account for about 60% of the variability in the incidence of psychiatric diseases, while a genetic predisposition appears to account for the remaining 40% [5, 6] . In this context it is of interest to note that there is a great overlap between anxiety and depression. The co-morbidity of, for instance, primary anxiety disorders and major depression is about 60% [7] . Surprisingly, this association has received little attention in animal research.
Unlike patients, a rat or a mouse can be equipped with microdialysis probes or electrodes to directly study neurobiological processes and mechanisms underlying anxiety-and fear-related behavior. Anxiety /fear is actually the only emotionality that is (indirectly) measurable in the rat or other rodents.
The crux of the objection to animal models of emotionality and psychopathology is that animals are not capable of telling us what they are feeling. Hence, all we can actually do is to monitor their locomotion and then trying to intepret their behavior in terms of factors underlying this locomotor activity. On a rough scale, such factors include anxiety, curiosity, caution and social affinity.
They can be dissected from each other by a factor analysis as an essential prerequisite to investigate the contribution of single factors, also called dimensions, to the regulation of emotionality.
This multidimensionality of emotionality [8, 9] is sometimes ignored and then, indeed, impaired locomotion, e.g. by muscular weakness or sedation, can be misinterpreted as anxiety. Often, appropriate behavioral analyses are still underestimated in studies primarily focused on, for instance, genetic manipulations or the monitoring of neuroendocrine correlates of anxiety/fear. Whatever the primary focus will be, one has to keep in mind that the experimental data can only be as good as the characterization of the behavioral phenotype. This, as mentioned before, is by no means trivial and requires a variety of behavioral tests including the elevated plus-maze, the open field, the hole board etc., which in most cases represent naturally occurring paradigms where rodents are challenged by the conflict between anxiety/fear on the one hand and exploratory curiosity on the other.
In particular the amount of time spent in the risky environment relative to the safe environment is used as an index of the animal's level of anxiety (an increase in exploratory behaviors toward the risky environment indicates a relatively low level of anxiety).
The range of physiological as well as pathological anxiety is orchestrated by a system of many genes, each probably with small effects. Accordingly, all signaling pathways in probably all brain areas are involved directly or indirectly in regulatory patterns underlying anxiety-related behavior.
There is no doubt that neuropeptides play a major role in this context.
III. Neuropeptides
By definition, neuropeptides are produced by neurons and are capable of eliciting effects on neuronal functions. In most cases, they are released intracerebrally from all parts of the neuronal membrane into the extracellular fluid of the brain, where they diffuse to act on relatively distant target cells. This type of signaling has been defined as "volume transmission" [l0] to emphasize the fact that, in principle, these neuropeptides can produce their effects as neuromodulators throughout the volume of the brain. In this mode of intercellular communication, pathways of signaling are defined primarily by the chemistry of the signal molecules and by the localization of their receptors rather than by the topological proximity of release and target sites. This by the way explains why a large number of different neuropeptides including their metabolites serve as modulators whereas relatively few "classical" transmitters are sufficient for the myriads of synapses present in the brain. The large number of neuropeptides evolved and evolves from the fact that they are primary products of protein biosynthesis and thus prone to direct changes by mutations.
In addition to their neuromodulator action, neuropeptides have been shown to act as transmitters, i.e. in pathways of signaling defined by the topological proximity of release and target sites. This complex involvement of neuropeptides in different signaling pathways helps to explain their multiple roles in brain functions such as behavioral regulation (including aggressive and sexual behaviors), cognition and emotionality. Whereas, thanks to the pioneering work of D. de Wied and his co-workers in the late sixties, compelling evidence has been accumulated that neuropeptides contribute to learning and memory, it has later been realized that their spectrum of actions also includes emotionality, in particular anxiety-related behavior.
While central (i.e. intracerebrally released) neuropeptides are likely to be involved in behavioral regulation, peripherally circulating peptides secreted into the blood do not seem to play a major role in this context. On the one hand the secretion of these neuropeptides may be independent of central release patterns (for example, vasopressin in the rat [11] ). This makes it unlikely that the central and peripheral neuropeptide subserve similar functions.
If released in parallel (for example, oxytocin in the rat [11] ), the central and peripheral neuropeptide may act synergistically. On the other hand, endogenous neuropeptides do not penetrate the bloodbrain barrier in physiologically relevant amounts. This together with the fact that most endogenous neuropeptides are present in the extracellular fluid of the brain in concentrations much higher than in plasma, make a penetration of plasma neuropeptides across the blood-brain barrier and their effects on neuronal functions highly unlikely. If, however, a synthetic neuropeptide or an analogue is administered peripherally in high doses, even a seemingly negligible brain uptake of < 0.5%-mainly through circumventricular organs [12] -may reach functional significance.
One more rather methodological remark: It is certainly not sufficient to simply administer the neuropeptide of interest in different doses to draw any conclusion as to its physiological involvement in anxiety-related behavior. It is conceivable, for instance, that all receptor sites are already occupied by the corresponding endogenous ligand or that closely related receptors are occupied by the synthetic neuropeptide. Hence, as a conditio sine qua non, the endogenous neuropeptide, its interaction with receptor site(s) and the receptor sites themselves have to be manipulated as selectively as possible to unravel the physiological impact of the neuropeptidergic pathway of interest. This strategy is often hampered by the fact that highly specific receptor antagonists are not available or, if available, show signs of agonistlike effects, at least at high concentrations, or even trigger an up-regulation of receptors. Therefore, to address the issue of physiological significance, more sophisticated approaches such as knock-out models, antisense targeting, and virally mediated gene transfer have additionally to be used, though they have their own limitations (see below).
Inversely, the activity of the neuropeptidergic system of interest in response to an anxiogenic stimulus or in an extreme phenotype of anxiety-related behavior has to be demonstrated. Only if data of this bilateral approach (from inside to outside and vice versa) fit together, compelling evidence will exist for a causal involvement of a given neuropeptide in anxiety-related behavior. As most of the published papers cannot use the whole spectrum of methodological approaches and the experimental evidence of a physiological significance differs among neuropeptides, any comparison of their effects should be made with caution.
Thus, the comparison of anxiolytic versus anxiogenic potencies of neuropeptides is hampered by the fact that anxiety-related effects appear to depend on at least three variables which are rarely similar: the neuropeptide per se, i.e. dose and administration, the brain site(s) involved, and the behavioral tests used. A plethora of preclinical and clinical data indicate that the corticotropin-releasing factor (CRF) and vasopressin are neuropeptides likely to play a crucial role in anxiety-related behavior [13] [14] [15] [16] [17] . First of all, they are ACTH secretagogues and as such central components of the hypothalamic-pituitary-adrenocortical (HPA) axis [1 8, 19] . The highest density of CRF-containing neurons is detectable in the hypothalamic paraventricular nucleus (PVN) with the majority of neurons projecting to the median eminence.
There, from axon terminals in the external zone, CRF is released into the portal blood.
In a portion of these PVN neurons vasopressin is co-expressed and co-localized together with CRF. Dependent upon the quality and intensity of a stressor, the CRF/vasopressin ratio released into the portal blood may vary [20] . CRF/vasopressin then reach the anterior pituitary, where they bind to receptors, and through a cascade of intracellular steps they ultimately give rise to pro-opiomelanocortin (POMC) gene expression and -inter aliathe secretion of ACTH.
This peptide, in turn, induces the synthesis and secretion of corticosterone (in rodents) or cortisol (in primates) from the adrenal cortex.
Subsequently, these glucocorticoids bind to mineralocorticoid and glucocorticoid receptors, thereby exerting negative feed-back on HPA axis activity.
Thus, the adaptive function of the HPA axis, for example in anxiogenic situations, is critically dependent on feedback mechanisms to dampen the stressor-induced activation of the HPA axis and to limit further ACTH and glucocorticoid secretion.
Although both CRF and vasopressin are important components of the HPA axis, their most salient behavioral effects are mediated outside the axis. Thus, in addition to their localization in the hypothalamic PVN, CRF-and vasopressin-containing neurons are widely distributed throughout the brain, including the neocortex, the septum, the amygdala and the bed nucleus of the stria terminalis, the locus coeruleus, and the raphe nuclei. Both neuropeptides, acting as neuromodulators and/or neurotransmitters in these areas, are believed to be important in several behavioral actions, including emotional and cognitive processing, neuroendocrine and autonomic functions, etc. For example, central administration of CRF triggers a variety of physiological and behavioral effects almost identical to those observed in response to an anxiogenic stressor. CRF projections originating in the amygdala are believed to play an important role in the expression of stress-induced responses distinct from the neuropeptide effects in the HPA axis. In this context it is of interest to note that plasma corticosterone correlates positively with CRF mRNA in the amygdala, and negatively with CRF mRNA in the PVN [21, 22] . The increase in PVN CRF mRNA after exposure to an acute anxiogenic stimulus appears to be a reliable phenomenon as it has been reported with a wide variety of stressors and by several different laboratories [e.g., 18, 23, 24] . Interestingly, stress-induced increases in PVN CRF gene expression can be attenuated by anxiety-reducing benzodiazepines [25] .
While central effects of intracerebrally released vasopressin [26] are mediated by the V 1 a receptor subtype, two specific G-protein-coupled seven-transmembrane domain CRF subtypes have been described which mediate the different known effects. CRF1 receptors are found predominantly in the pituitary and the brain, particularly in hypothalamic, neocortical and limbic structures. The CRF2 receptor subtype is more abundant in the periphery, but is also found in subcortical brain areas such as the lateral septum and various hypothalamic areas [27] . Recently, two splice variants of the CRF2 receptor have been characterized in the rat brain [28] . Both variants are likely to be involved in the central effects of CRF and urocortin, a recently isolated 40 amino acid-containing neuropeptide (for new structurally related members of the CRF family of neuropeptides see [29] ), in a differentiated manner. The highest density of urocortin expression and innervation occurs in regions that nearly exclusively express CRF2 receptor mRNA, indicating that urocortin is the endogenous CRF2 receptor ligand. Interestingly, it binds and activates CRF1 receptors with greater potency than CRF itself [30] . In the hypothalamic supraoptic nucleus, urocortin was found to be localized to vasopressin and oxytocin neurons but was rarely seen in CRF-positive cells [31, 32] . Also CRF was detectable in magnocellular neurons of both the supraoptic and paraventricular nuclei. Since, in the same neurons, the CRF1 receptor is expressed [32] , the neuropeptides CRF, urocortin, vasopressin, and oxytocin are likely to closely interact at the level of the hypothalamo-pituitary tract including the magnocellular system. This interaction and the contribution of the magnocellular system might play a role not only in the regulation of HPA axis activity, but also of cognitive and emotional functions.
Increases in intracerebral CRF levels via central administration or through stimulated release patterns have been found not only to upregulate the expression of the CRF gene, but also of the CRF1 receptor gene. In contrast, the CRF2 receptor gene remained unaffected [33] [34] [35] . Taken together, there are multiple sites at which anxiogenic stimuli might impinge simultaneously on the various elements of the CRF and vasopressin systems and thereby influence the expression and function of these critical neuropeptides under a variety of conditions.
IV.
Involvement of neuropeptides in anxiety-related behavior
CRF
As mentioned above, the central administration of CRF triggers behavioral and physiological effects almost identical to those in response to a stressor including hyper-anxiety, suppression of exploratory behavior in an unfamiliar environment and decreased food intake and sexual behavior. The behavioral effects of centrally administered CRF can be reversed by CRF receptor antagonists, but not by dexamethasone pretreatment; therefore they appear to be independent of HPA axis activation. Furthermore, the antagonist alone attenuates many of the behavioral consequences of stressor exposure, underscoring the role of endogenous CRF in mediating many stress-induced behaviors. While the majority of approaches using synthetic ligands (CRF, urocortin) or antagonists confirmed an anxiogenic-like potency of CRF, some behavioral tests failed to reveal this effect, indicating that different neuronal circuits may be involved in the many facets of anxietyrelated behavior. Furthermore, an adequate level of CRF seems to be necessary in maintaining central nervous functions while a lack or an excess of CRF could impair those functions.
Molecular biological techniques have been used to examine the importance of each of the CRF receptor subtypes in the regulation of emotionality. Antisense oligodeoxynucleotides directed against CRF1 receptors in the amygdala have anxiolytic effects [36] , refining the actions of CRF even further. These results were subsequently confirmed in a separate study after intracerebroventricular antisense administration [37] . While, again, CRF1 but not CRF2 receptor antisense oligodeoxynucleotide was found to reduce anxiety-related behavior of socially defeated rats, CRF2 but not CRF1 antisense targeting was shown to selectively influence stress-coping behavior in a forced swim test. Likewise, a differential involvement of CRF1 and CRF2 receptor subtypes in learning and memory abilities has recently been shown by Radulovic et al. [38] . Interestingly, the dose of CRF required for induction of anxiety-related behavior was higher than the dose that modulated learning. Septal CRF2 receptors were shown to play a role in the former.
There is conflicting evidence with respect to the role for urocortin in the regulation of anxiety-related behavior, mostly due to the fact that, following central administration, urocortin has access to both CRF receptor subtypes. While, in this context, the anxiogenic effects of urocortin through actions at the CRF1 receptor are of questionable physiological relevance, the CRF2 receptor is likely to mediate anxiolytic and stress-coping effects [39, 40] .
There are strong functional interactions between CRF and the raphe nuclei and the locus coeruleus [41] , the origin of the major serotonergic and noradrenergic projections to the forebrain, respectively, circuits long postulated to play a role in the pathophysiology of anxiety and depression [7] . CRF injected into the locus coeruleus intensifies anxietyrelated behavior [42] suggesting that locus coeruleus noradrenergic neurons may play a pivotal role in the anxiogenic properties of CRF. Accordingly, microinfusions of CRF directly into the locus coeruleus increase the firing rate of locus coeruleus neurons in a dose-dependent manner and produce an increase in noradrenaline measured by in vivo microdialysis. Infusion of the CRF antagonist alpha-helical CRF into the locus coeruleus attenuates the stress-induced release of noradrenaline in the prefrontal cortex. In turn, noradrenaline increases CRF in the PVN. Other results [43, 44] implicate CRF receptors in the amygdala and the bed nucleus of the stria terminalis as primary sites for CRF-induced effects.
An important aspect of neuropeptide/anxiety interactions lies in the fact that trait as well as state anxiety may differ among outbred (and even inbred) animals.
As an example, Wistar rats purchased from a commercial supplier, differ distinctly in their anxiety-related behavior although they are thought to be relatively homogenous in this parameter. Accordingly, they may easily be separated into anxious vs. non-anxious groups which then reveal divergent behavioral characteristics [45] . Particularly in experiments focusing on emotionality, this variability has to be taken into account.
It is not only likely to influence "basal" anxiety behavior, but also the behavioral and neuroendocrine responses to stressful challenges and drugs.
This variability is determined both genetically
[46] and epigenetically by nongenomic mechanisms [47] . Likewise, two studies have shown that alpha-helical CRF 9-41 produced anxiolytic-like effects in the elevated plus-maze only after animals had been stressed by exposure to conspecific aggression [48, 49] . In line with these findings is the paper by Conti et al. [50] , who showed that alpha-helical CRF 9-41 was more efficacious in BALB/c mice, which are described as "emotional" than in three "non-emotional" strains (i.e. NIH Swiss, CF-1, CD) on the elevated plus-maze. Studies with other CRF receptor antagonists further support the hypothesis that trait/state levels of anxiety are critical when studying the behavioral effects of such compounds.
For example, peripheral administration of the nonpeptide CRF receptor antagonist CP-154,526 elicited anxiolytic-like effects in the rat only if mean baseline levels of exploration of the aversive parts of the maze were low [51, 52] .
Likewise, rats with inborn hyper-anxiety (HAB) bred in my laboratory for more than a decade [53] [54] [55] [56] ( Fig. l) were shown to respond to the CRF 1 receptor antagonist R 1219i9, while hypo-anxious rats (LAB) failed to alter their level of anxiety-related behavior [57] (Fig. 2) . Inversely, in the same psychopathological rat model, synthetic CRF given intracerebroventricularly induced marked anxiogenic effects in hypo-anxious rats only. Interestingly, the anxiolytic effects of the CRF antagonist in hyper-anxious ani-mals were independent of the dose-dependent attenuation of the HPA activity in the same rats, further confirming that behavioral alterations and HPA axis activity are not necessarily closely linked phenomena. Thus, similar to patients vs. control subjects, only animals bearing a clear-cut deficit are prone to reveal the potential of agents as anxiolytic drugs, thereby providing an ideal model to study neuropeptide effects on emotionality and, vice versa, neuropeptidergic correlates of extreme emotionality. As many signs and symptoms of anxiety disorders and depression can be attributed to an enhanced activity of CRF neurons which act through the CRF1 receptor subtype [14, 16] , the pharmacological properties and anxiolytic effects of R121919 in hyper-anxious rats render this antagonist a promising lead for use in psychiatry. First clinical experience supports this notion [58] . Finally, confirming antagonist and antisense approaches, molecular genetic studies have found reduced anxiety-related behavior in CRF receptor 1-null mice [59, 60] . Interestingly, in these animals, a selective compensatory activation of the hypothalamic vasopressinergic, but not the oxytocinergic system has been described to maintain basal ACTH secretion and HPA axis activity [61] (Fig. 3) . In comparison to the CRF1 receptor knock-out mice, CRF2 receptor knock-out mice seem to display a different and also less consistent phenotype [62] [63] [64] suggesting emotional facets to be more variable in this knock-out phenotype. Some of those mutants, for example, showed decreased open arm entries in the elevated plus-maze [62, 64] , whereas others failed to exhibit any change in this measure of anxiety [63] . Central over-expression of CRF in transgenic mice resulted in hyper-emotionality and impaired learning and retention in several spatial tasks, an impairment Indeed, as shown in a recent study [67] , our psychogenetically selected hyper-anxious HAB rats display a significant decrease in basal CRF mRNA levels in the bed nucleus of the stria terminalis.
Importantly, administration of CRF directly into the bed nucleus of the stria terminalis facilitated anxiety/fear-related behavioral responses; CRF receptor antagonists into this area did the converse [4, 44] . Furthermore, there was a trend toward increased basal CRF mRNA levels in the hypothalamic PVN. While CRF1 receptor binding failed to differ between the lines, hyper-anxious HAB rats displayed an increased CRF2 receptor binding in the PVN and ventromedial hypothalamus.
Compared to CRF, much less is known about conditions that influence the expression of the CRF receptor genes. Therefore, although these differences are difficult to interpret at present, they nonetheless indicate an involvement of CRF pathways in distinct brain areas in the differences of innate anxiety-related behavior.
Taken together, CRF provides an example of an anxiogenic neuropeptide excellently characterized by multiple approaches.
Nevertheless, all of the methods used in this context have their own limitations and none of them, if used alone, is likely to provide clear-cut information.
Transgenic and knock-out approaches may be less useful for identifying the discrete functions of a certain gene product because of the problems of interpretation that arise from the developmental confounds. Compensatory alterations in the CRF system have to be taken into account that may occur during development in response to the congenital mutation and that may indirectly contribute to the behavioral phenotype which is difficult to assess [68] . The problem can be overcome by new systems that allow inducible and tissue-specific knock-out of genes or expression of transgenes [69] . Antisense targeting, on the other hand, has to minimize toxicity and maximize efficacy; furthermore, this technique suffers from frequently inappropriate controls [70, 71] . Based on genetic heterogeneity, robust behavioral phenotypes can be bred differing extremely in emotionality.
But even breeding strategies have their pitfalls.
It is unclear, for example, whether the differential gene expression patterns are the cause or the result of the different phenotypes observed in the separate lines.
A promising approach to the molecular analysis of behavior involves the use of viral vectors.
This ap- [72] succeeded in expressing the vole Via receptor subtype in the mouse brain, thereby increasing the affiliative response to vasopressin. Unilateral expression of the same receptor subtype in the septal area of the rat brain resulted in a marked improvement of cognitive functioning [73].
Vasopressin
While not studied in as much depth as CRF and while central vasopressin projections are thought to be primarily involved in cognition [74] , vasopressin is likely to play a role in emotionality. Using antisense targeting, we provided compelling evidence for septal Via receptors being involved in the regulation of anxiety-related behavior of rats as scored on the elevated plus-maze. Transient and selective downregulation in septal receptor density resulted not only in marked cognitive deficits, but also in a reduced anxiety compared to controls (vehicle, mixed bases, sense) [75] . In a follow-up experiment [76] , synthetic vasopressin was administered by inverse microdialysis to mimic intraseptal release patterns as closely as possible. While a dose of vasopressin of as low as 0.25 ng (delivered over a 30-min retrodialysis period) failed to alter plus-maze behavior, rats treated with a V 1 receptor antagonist (5 ng over a 30-min retrodialysis period) made significantly more entries into and spent more time on the open arms of the maze, indicating reduced anxiety-related behavior. Neither vasopressin nor its antagonist influenced locomotor activity of the rats. These data give rise to the hypothesis that vasopressin acts at the level of the septum to coordinate different central functions such as learning, memory and emotionality, which, in concert, determine adequate behavioral responses of an animal to environmental demands. Whereas Bhattacharya et al. [77] confirmed an anxiogenic effect of central vasopressin, Appenrodt et al. [78] found anxiolytic effects of both centrally and peripherally administered vasopressin.
Again, the physiological impact of this neuropeptide has to be confirmed in animal models of inborn hyper-versus hypo-anxiety. Remarkably, under both basal and stressful conditions, more vasopressin mRNA is detectable in the PVN of hyper-anxious HAB than LAB animals without any difference in oxytocin mRNA [67] . mRNA and peptide levels, however, are not necessarily regulated in the same manner by a particular manipulation or event. Therefore, in addition to its increased expression, vasopressin release patterns under basal conditions and upon stimulation have recently been measured by microdialysis in freely behaving rats. It turned out that more vasopressin is released within the PVN of HAB vs. LAB rats [67] suggesting centrally released vasopressin to play a major role in the hyper-reactive HPA axis of the former [56] (Fig. 4) . This is strongly supported by Keck et al. [79] , who succeeded in showing the pathophysiological relevance of an overproduction of vasopressin in HAB rats. In more detail, the pathological outcome of the dexamethasone/CRF test in HABs (i.e. both elevated plasma levels of ACTH and response to synthetic CRF despite prior dexamethasone administration) could be abolished by co-administration of a Vi receptor antagonist. Further studies are needed to character- The same animals were initially tested on the maze four weeks before the experiment; for the percent of time spent on open arms see inset graph. From Landgraf et al. [56] . ize the contribution of over-expressed and over-released vasopressin to neuroendocrine and behavioral phenomena in this psychopathological animal model in more detail.
The same holds true for the hyperand hypo-emotional Roman low and high avoidance rats, originally selected and bred for poor versus rapid acquisition of two-way active avoidance response.
In the former, more ACTH and corticosterone are secreted upon a mild stressor, again indicating a hyper-reactive HPA axis. This was shown to be associated with higher vasopressin mRNA levels in the PVN, whereas CRF mRNA did not differ between the lines [80] .
In view of the wide range of CRF and vasopressin effects on anxiety-related behavior one can hypothesize that-similar to but independent of HPA axis regulationboth neuropeptides in varying ratios may shape emotionality dependent on the intensity and quality of the anxiogenic stimulus.
Oxytocin
In addition to its well-known reproductive functions, oxytocin released within the mammalian brain is known to be involved in a variety of regulatory pathways including those underlying social, sexual, and maternal behaviors [26, 81, 82] and depressionlike behavior [83] . Following peripheral [84] or central [85] administration, an anxiolytic-like effect has been described in rats. Oxytocin infused into the central nucleus of the amygdala, but not the ventromedial nucleus of the hypothalamus, was anxiolytic indicating brain region-specific effects [86] . Recently, Neumann et al. [87] succeeded in showing that a specific oxytocin antagonist given centrally significantly enhanced the anxiety-related behavior in both pregnant and lactating rats, without exerting similar effects in virgin female or male animals. Thus, the anxiogenic effects of the oxytocin antagonist appear to depend on the cycle-stage revealing an anxiolytic action of central oxytocin only at a time when the brain oxytocin system is highly activated. Along the same line, reduced anxiety-related behavior has been shown previously in lactating rats [88] . These reproduction-dependent behavioral alterations might be related to the complex pattern of maternal behavior, which includes an increased aggressive behavior toward conspecifics in order to protect the offspring [89] . Thus, activation of the central oxytocin system during the peripartum period [90] may be related not only to the onset of maternal behavior to provide nutritional and social support for the young, but also to the reduction in anxiety-related behavior necessary for their protection [87] . Central administration of substance P has been found to induce anxiogenic effects in the elevated plus-maze [106, 107] , whereas administration of substance P antagonists produced anxiolysis in different tests of anxiety [108] . Again, it seems that these effects depend on both the neuropeptide dose and the specific brain region [109, 110] . Recently, both genetic disruption and pharmacological blockade of the NK1 receptor in mice resulted in a reduction of anxiety and stress-related responses as well as in a selective desensitization of 5-HT1A inhibitory autoreceptors, which resembles the effect of sustained antidepressant treatment [111].
Prolactin
Convincing evidence of an anxiolytic action of both exogenous and endogenous prolactin has recently been provided by Torner et al. [112] . While intracerebral infusion of this neuropeptide exerted anxiolytic effects on the elevated plus-maze in a dosedependent manner in both male and female rats, downregulation of the long form of the prolactin receptor by highly efficient antisense targeting resulted in increased anxiety-related behavior.
In addition to its behavioral action, prolactin was shown to attenuate the responsiveness of the HPA axis to an emotional stressor [112].
Other Neuropeptides
Another neuropeptide that is involved in anxiogenic and fearful responses is calcitonin gene-related peptide [113] . Likewise, central administration of angiotensin II in the rat increases anxiety-related behavior [1 14] . Accordingly, transgenic rats accumulating angiotensin II in the brain exhibit signs of hyper-anxiety [115] . On the other hand, mice lacking the angiotensin II type-2 receptor displayed increased anxiety-related behavior [116] but mice lacking angiotensinogen did not differ in their anxietyrelated behavior from controls [117] .
Other neuropeptides thought to induce anxiolytic effects, include nociceptin (orphanin FQ [118] , galanin [1 19 ], atrial natriuretic peptide [120] , and enkephaline [121] . More work is needed to reveal and to confirm the physiological significance of these neuropeptides in the regulation of anxiety-related behavior. 
